Drug intelligence / Profile preview

bevacizumab + olaparib + durvalumab

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A triple combination therapy consisting of bevacizumab (an anti-VEGF monoclonal antibody), olaparib (a PARP inhibitor), and durvalumab (an anti-PD-L1 monoclonal antibody). This combination targets multiple pathways in cancer treatment: inhibiting angiogenesis, preventing DNA repair in cancer cells, and enhancing immune response against cancer cells. The synergistic effect is particularly notable in ovarian cancer treatment, where bevacizumab creates a hypoxic environment that may increase sensitivity to PARP inhibition by olaparib, while durvalumab counteracts immunosuppression in the tumor microenvironment.

Brand names: Imfinzi + Avastin + Lynparza
Other names: durvalumab + bevacizumab + olaparib

Targets

VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on bevacizumab + olaparib + durvalumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + olaparib + durvalumab.

Explore the full profile